The Food and Drug Administration has released guidelines for e-cigarette makers. The instructions include information about how e-cigarettes should be marketed and how companies should address public health issues. (Reuters)
Private insurance will be required to cover preventive HIV medicine at no cost. The The U.S. Preventive Services Task Force gave PrEP treatments a grade-A recommendation, which means private insurers must cover the drug. (CNBC)
Juul said sales are recovering after a dip last year. The company told investors that Q1 sales were $528 million, 23% higher than last year. Juul said the 2018 dip was caused by pulling some flavored vape pods off the market. (Bloomberg)
The FDA is holding a two-day hearing about the benefits and risks of high doses of opioids. The agency is weighing whether to reduce the use of high daily doses of opioids. The FDA is hearing comments from experts and the public about the clinical benefits and potential risk of these drugs. (BioPharma Dive)
Keytruda has been approved for a new indication to treat a type of head and neck cancer. The treatment won FDA approval for head and neck squamous cell carcinoma, which can include tumors in the mouth, tongue, nose, sinuses, throat and lymph nodes in the neck. (Reuters)
